文献速递中医内科中药与中成药合理使用

益气活血中药辅助治疗高血压性心脏病进展的系统评价与Meta分析

Potential preventive effects of selected traditional Chinese medicine as adjuvant therapy on hypertensive heart disease progression by replenishing qi and activating blood circulation: a systematic review and meta-analysis of clinical trials.
PubMed 文献 · Front Pharmacol · 2025-10-02

Meta分析显示,中药联合西药在血压、心功能分级、左室射血分数、E/A比值、左室内径、左室质量指数、室间隔厚度及BNP等指标上优于单用西药,未发现严重不良事件。

要点

  • 益气活血中药联合西药可改善高血压性心脏病患者的心脏重构和功能。
  • 纳入研究未报告严重不良事件,但心脏输出量结果需谨慎解读。
  • 常用中药包括丹参、川芎、葛根、黄芪和蒲黄,多为经典方剂口服制剂。

核心结论

  • 益气活血中药作为辅助治疗可能减轻高血压性心脏病患者的不良左室重构并改善心脏功能。

主要发现

  • 与单用西药相比,中药联合西药在血压、NYHA分级、左室射血分数、E/A比值、左室内径、左室质量指数、室间隔舒张期厚度和B型利钠肽等指标上更优。
  • 心脏输出量结果因样本量限制需谨慎解读,未发现严重不良事件。

关键数值与推荐

  • 采用均数差(MD)和95%置信区间(CI)评估连续变量,风险比(RR)和95%CI评估二分类变量。
  • 使用GRADE工具评估证据质量。

临床怎么用

  • 对于高血压性心脏病患者,可考虑在规范西药治疗基础上联合益气活血中药以改善心脏结构和功能。
  • 常用中药包括丹参、川芎、葛根、黄芪和蒲黄,多为经典方剂口服制剂。

局限性

  • 需要更多长期、高质量的随机对照试验来进一步评估中药的预防效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Hypertension remained an important public health problem with high morbidity and mortality and was emerging as a risk factor for future heart failure. The transition from hypertension to hypertensive heart disease (HHD) and heart failure grew progressively with time. Traditional Chinese medicine (TCM) has a history of several thousand years, where selected TCM for replenishing qi and activating blood circulation provides an alternative treatment for HHD. METHODS: An extensive literature search was conducted across eight electronic databases from their inception until 8 September 2023, to evaluate the potential preventive effects of selected TCM as an adjuvant therapy on the progression of HHD. The outcome measures included blood pressure and indicators of cardiac structure and function under cardiac ultrasound. The mean difference (MD) and 95% confidence interval (CI) were used to determine continuous outcomes. Risk ratio (RR) with 95% confidence interval (CI) was used to determine dichotomous outcomes. The information about the overall certainty of the evidence from studies was presented according to specific outcomes using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Guideline Development Tool (GDT) online software. RESULTS: Twenty-one randomized controlled trials (RCTs) involving 2, 055 participants were included. Meta-analyses favored integrated Chinese botanical drugs and Western medicine on blood pressure, New York Heart Association classification, left ventricular ejection fraction, transmitral peak early diastolic velocity/peak late diastolic velocity ratio, left ventricular internal diameters, left ventricular mass index, interventricular septum thickness in diastole, and B-type natriuretic peptide compared with Western medicine alone. Results on cardiac output should be interpreted with caution due to sample size limitations. No severe adverse events were identified. Most of the Chinese botanical drugs originated from classical TCM formulas. The dosage form of Chinese botanical drugs was oral. Salvia miltiorrhiza Bunge (Danshen), Oreocome striata (DC.) Pimenov & Kljuykov (Chuanxiong), Pueraria montana var. lobata (Willd.) Maesen & S.M.Almeida ex Sanjappa & Predeep (Gegen), Astragalus mongholicus Bunge (Huangqi), and Typha angustifolia L. (Puhuang) were the top 5 Chinese botanical drugs, which might be associated with replenishing qi and activating blood circulation. CONCLUSION: Selected TCM had the potential to be effective as an adjuvant therapy for alleviating adverse left ventricular remodeling and improving cardiac function after HHD, and therapy of replenishing qi and activating blood circulation may serve as a potential reference for treatment. To better assess Chinese botanical drugs' preventative effects, more long-term, high-quality RCTs are still necessary. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/#myprospero, identifier CRD42022346030.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Hui J, Wang Y, Xu F, et al. Potential preventive effects of selected traditional Chinese medicine as adjuvant therapy on hypertensive heart disease progression by replenishing qi and activating blood circulation: a systematic review and meta-analysis of clinical trials. Front Pharmacol. 2025. PMID: 41111519. doi:10.3389/fphar.2025.1506234

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。